Zydus Lifesciences Limited has informed the Exchange regarding a press release dated April 06, 2023, titled "(1) Zydus receives final approval from the USFDA for Acetazolamide Tablets USP, 125 mg and 250 mg and (2) Zydus receives final approval from the USFDA for Carbidopa and Levodopa Tablets USP, 10 mg/100 mg, 25 mg/100 mg, and 25 mg/250 mg ".
Press Release Apr 06 2023
Filed with NSE · · 3 pages · English
Summary by 6ix AI
Zydus Lifesciences Limited has issued a press release detailing two recent approvals from the USFDA for its products. The first approval is for Acetazolamide Tablets USP, which are used to treat glaucoma and altitude sickness, among other conditions. The second approval is for Carbidopa and Levodopa Tablets USP, used to treat symptoms of Parkinson's disease. Both products will be manufactured at Zydus's facilities in India.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
Release
Zydus Lifesciences Limited on 6ix
Earlier from Zydus Lifesciences
- Press Release Mar 28 2023
- Press Release Mar 25 2023
- Press Release Mar 24 2023
- Press Release Mar 21 2023
- Press Release Mar 15 2023
Later from Zydus Lifesciences
- Press Release Apr 10 2023
- Press Release Apr 11 2023
- Press Release Apr 15 2023
- Press Release Apr 18 2023
- Press Release Apr 19 2023
Follow Zydus Lifesciences into a list and get an email when it puts out news.
Follow Zydus Lifesciences